Unusual Volume Spikes For: ImmunoGen, Inc. (NASDAQ:IMGN)

ImmunoGen, Inc. (NASDAQ:IMGN)

H.C. Wainwright Initiates Coverage On ImmunoGen, Inc. (NASDAQ:IMGN)’s stock to Buy with the price target of $18. This rating was issued on 1/31/18. The stock recently closed its previous session at $7.68 by showing a percentage change of 0.2% from its previous day closing price of $7.66.

Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Several investment firms issued their expert ratings on ImmunoGen, Inc. (NASDAQ:IMGN) in which Canaccord Genuity Maintains ImmunoGen, Inc. (NASDAQ:IMGN) to Buy by settling a price target of $10 on 8/31/17. Morgan Stanley Maintains the stock to Underweight on 7/10/17 by stationing a price target of $1.4. RBC Capital Upgrades the company’s stock to Outperform on 7/06/17 with no specific Price Target. JP Morgan Maintains ImmunoGen, Inc. (NASDAQ:IMGN) to Neutral with a price target of $5.

ImmunoGen, Inc. (NASDAQ:IMGN) currently has a consensus Price Target of $14.33. While some analysts have a High Price target for the stock of $20 and a Low Price Target of $3.

Several sell side analysts reviewed their recommendations on ImmunoGen, Inc. (NASDAQ:IMGN) where 5 analyst have rated the stock as Strong Buy, 3 analysts said it’s a Buy, 2 rated the stock as Hold, 1 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)

Zacks Investment Research also rated the stock with a value of 1.91. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, ImmunoGen, Inc. (NASDAQ:IMGN) reported its Actual EPS of $-0.31/share. The analysts offering Earnings Estimates for the company were believing that ImmunoGen, Inc. (NASDAQ:IMGN) could bring EPS of $-0.29/share. The difference between Actual EPS and Estimated EPS was -0.02 Percent. Thus the company showed an Earnings Surprise of -6.9 Percent.

ImmunoGen, Inc. (NASDAQ:IMGN) has a market capitalization of 1.14 Billion. The stock traded with the volume of 2.74 Million shares in the last trading session. The stock touched its high share price of $13.41 on 03/26/18 and the stock also touched its Lowest price in the last 52-weeks of trading on 11/03/17 as $4.80. The company has a 1 Year high price target of $15.13. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of -14%. The Moving Average SMA50 is -16.37% while SMA200 is -22.32%.

ImmunoGen, Inc. (NASDAQ:IMGN) is currently showing its ROA (Return on Assets) of -51.5%. The Return on Investment (ROI) is at 371% while it’s Return on Equity (ROE) value stands at 786.5%. The stock currently shows its YTD (Year to Date) performance of 19.81 percent while its Weekly performance value is -11.42%. The Monthly and Yearly performances are -17.86 percent and 16.01 percent respectively. The Relative Volume value measured for ImmunoGen, Inc. (NASDAQ:IMGN) is 1.54. The Average Volume (3 months) is 1.78 Million.

The stock currently has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. IMGN has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 3.64 and Price to Free Cash Flow (P/FCF) value of 0. The stock is showing its Operating Margin of 0 percent.

Company Profile:

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company’s product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody.